Stockchase Opinions

Peter Hodson ID Biomedical IDB-T BUY ON WEAKNESS Jul 29, 2003

Developing a flu vaccine. Well cashed up. Would buy it, but at a lower level.
$17.540

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

PAST TOP PICK
(Was a top pick on Dec 21 up 50%) Can still go higher.
BUY
Still has substantial upside. Into some interesting products.
WEAK BUY
Very volatile. Well managed and has a lot of cash.
BUY
Good product. In final phases of testing.
BUY ON WEAKNESS
Likes the story. Has had a pretty good run, but has more room to go. Very strong news out of the company. Some trial results still to come out in the next little while.
BUY
The pharmaceutical sector has been torn apart. This company that has done a very good job in managing and developing some products.
DON'T BUY
Biotech stocks are very risky. This one has done very well on the flu vaccine problem in the US. A low margin business. Very expensive.
BUY
Have a large vaccine contract in the US. Should have a large increase in earnings and the stock should have a lot of upside.
HOLD
GlaxcoSmithKline (GSK-N) is taking the company over. Speculation is that someone else will come in with a better offer. Can't see much risk in holding on to your shares.